(S)-1-((S)-2,6-Diaminohexanoyl)pyrrolidine-2-carboxylic acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (S)-1-((S)-2,6-Diaminohexanoyl)pyrrolidine-2-carboxylic acid
• 英文别名: 1-(2,6-diaminohexanoyl)pyrrolidine-2-carboxylic acid
• 化学式: C₁₁H₂₁N₃O₃
• 分子量: 243.3
• InChiKey: AIXUQKMMBQJZCU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -3.3
• 重原子数：
  17
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.82
• 拓扑面积：
  110
• 氢给体数：
  3
• 氢受体数：
  5

文献信息

• [EN] PROCESS FOR THE PRODUCTION OF LISINOPRIL<br/>[FR] PROCEDE DE PRODUCTION DE LISINOPRIL
  申请人：EOS ECZACIBASI OZGUN KIMYASAL

  公开号：WO2004000874A1

  公开（公告）日：2003-12-31

  The present invention provides a process for preparing N2-[1(S)-ethoxycarbonyl-3-phenylpropyl]-N6-trifluoroacetyl-L-lysine and lisinopril thereof. Lisinopril shows excellent angiotensin converting enzyme inhibitor activity. Friedel-Crafts acylation of benzene with maleic anhydride in the presence of AlCl¿3? affords trans-β-benzoylacrylic acid. Treatment of benzoylacrylic acid with HCl gas in ethanol gives ethyl 2-chloro-4-oxo-4-phenylbutyrate in high yield. The coupling reaction between ethyl 2-chloro-4-oxo-4-phenylbutyrate and trifluoroacetyl-L-lysine benzyl ester in the presence of a base pair and sodium iodide produces alkyl lydine derivative with a good diastereoselectivity. Catalytic hydrogenation of lysine derivative with palladium gives N?2¿-[1(S)-ethoxycarbonyl-3-phenylpropyl]-N6-trifluoroacetyl-L-lysine. This intermediate is activated to form cyclic N-anhydride by using N,N-carbonyldiimidazole and coupled with L-proline methyl ester hydrochloride to give fully protected lisinopril derivative, which is converted into crude lisinopril by hydrolysis.

  本发明提供了一种制备N2-[1(S)-乙氧羰基-3-苯基丙基]-N6-三氟乙酰-L-赖氨酸及其琥珀酸二乙酯盐（Lisinopril）的方法。Lisinopril表现出优异的血管紧张素转换酶抑制活性。在AlCl3存在下，苯与马来酸酐进行Friedel-Crafts酰化反应，得到反式-β-苯甲酰丙烯酸。将苯甲酰丙烯酸与HCl气体在乙醇中处理，高收率得到乙酸2-氯-4-氧代-4-苯基丁酯。在碱对和碘化钠存在下，乙酸2-氯-4-氧代-4-苯基丁酯与三氟乙酰-L-赖氨酸苄酯进行偶联反应，产生具有良好对映选择性的烷基赖氨酸衍生物。使用钯进行催化氢化，得到N2-[1(S)-乙氧羰基-3-苯基丙基]-N6-三氟乙酰-L-赖氨酸。使用N,N-羰基二咪唑激活该中间体形成环状N-酐，并与L-脯氨酸甲酯盐偶联，形成完全保护的Lisinopril衍生物，通过水解转化为粗Lisinopril。
• Process for the production of lisinopril
  申请人：ASLAN TUNCER

  公开号：US20070093664A1

  公开（公告）日：2007-04-26

  The present invention provides a process for preparing N 2 -[1(S)-ethoxycarbonyl-3-phenylpropyl]-N 6 -trifluoroacetyl-L-lysine and lisinopril thereof. Lisinopril shows excellent angiotensin converting enzyme inhibitor activity. Friedel-Crafts acylation of benzene with maleic anhydride in the presence of AlCl 3 affords trans-β-benzoylacrylic acid. Treatment of benzoylacrylic acid with HCl gas in ethanol gives ethyl 2-chloro-4-oxo-4-phenylbutyrate in high yield. The coupling reaction between ethyl 2-chloro-4-oxo-4-phenylbutyrate and trifluoroacetyl-L-lysine benzyl ester in the presence of a base pair and sodium iodide produces alkyl lydine derivative with a good diastereoselectivity. Catalytic hydrogenation of lysine derivative with palladium gives N 2 -[1(S)-ethoxycarbonyl-3-phenylpropyl]-N 6 -trifluoroacetyl-L-lysine. This intermediate is activated to form cyclic N-anhydride by using N,N-carbonyldiimidazole and coupled with L-proline methyl ester hydrochloride to give fully protected lisinopril derivative, which is converted into crude lisinopril by hydrolysis.

  本发明提供了一种制备N2-[1（S）-乙氧羰基-3-苯基丙基]-N6-三氟乙酰-L-赖氨酸及其L-赖氨酸普利类的方法。L-赖氨酸普利类表现出优异的血管紧张素转换酶抑制剂活性。苯基与马来酸酐在AlCl3存在下的Friedel-Crafts酰化反应得到顺式-β-苯甲酰丙烯酸。将苯甲酰丙烯酸与乙醇中的HCl气体处理，可以高产率得到乙酸2-氯-4-氧代-4-苯基丁酯。在碱对和碘化钠存在下，乙酸2-氯-4-氧代-4-苯基丁酯与三氟乙酰-L-赖氨酸苄酯进行偶联反应，产生具有良好对映选择性的烷基赖氨酸衍生物。用钯进行催化氢化，得到N2-[1（S）-乙氧羰基-3-苯基丙基]-N6-三氟乙酰-L-赖氨酸。使用N，N-碳酰亚咪唑激活该中间体形成环状N-酐，并与L-脯氨酸甲酯盐酸盐偶联，得到完全保护的L-赖氨酸普利类衍生物，通过水解转化为粗制L-赖氨酸普利类。
• Detection of Bacteroides gingivalis
  申请人：THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK

  公开号：EP0292708A2

  公开（公告）日：1988-11-30

  The present invention relates to the detection of B. gingivalis by the specific ability of B. gingivalis to hydrolyze N-carbobenzoxy-glycyl-glycyl-L-arginine-B-napthylamide deriva­tives. The present invention also relates to the use of assay systems which inhibit serum amino peptidase and enhance the detection of the B. gingivalis N-CBz-Gly-Gly-Arg peptidase. The assay system inhibits the serum enzyme by the use of a serum aminopeptidase inhibitor which inhibits the activity of serum aminopeptidase to a greater extent than it inhibits the activity of B. gingivalis N-CBz-Gly-Gly-Arg peptidase. The assay system also increases the reliability of detection of the B. gingivalis enzyme by the use of enhancing materials which enhance the enzyme activity of B. gingivalis N-CBz-Gly-Gly-Arg peptidase to a greater extent than such materials enhance the enzyme activity of serum aminopeptidase.

  本发明涉及通过牙龈杆菌水解 N-羧基苯氧基-甘氨酰-甘氨酰-L-精氨酰-B-萘酰胺衍生物的特异性能力来检测牙龈杆菌。本发明还涉及抑制血清氨基肽酶并提高牙龈杆菌 N-CBz-Gly-Gly-Arg 肽酶检测能力的检测系统的使用。该检测系统通过使用血清氨基肽酶抑制剂来抑制血清酶，该抑制剂对血清氨基肽酶活性的抑制程度大于对牙龈杆菌 N-CBz-Gly-Gly-Arg 肽酶活性的抑制程度。该检测系统还通过使用增强材料提高牙龈杆菌 N-CBz-Gly-Gly-Arg 肽酶的酶活性，其增强程度大于此类材料对血清氨肽酶酶活性的增强程度，从而提高检测牙龈杆菌酶的可靠性。
• Process for the synthesis of semisynthetic glycosaminoglycans with heparin or heparan structure modified in position 2 of the alpha-L-iduronic-2-0-sulfate acid
  申请人：ALFA WASSERMANN S.p.A.

  公开号：EP0618234A1

  公开（公告）日：1994-10-05

  A process for the synthesis of semi-synthetic glycosaminoglycans of general formula III with heparin or heparan structure modified in position 2 of the α-L-iduronic-2-O-sulfate acid in which the sulfate group is, entirely or in part, substituted with a nucleophilic radical is described. Said process is carried out by treating glycosaminoglycans with heparin or heparan structure by means of a nucleophilic agent in alkaline medium.

  本发明描述了一种通式 III 的半合成氨基聚糖的合成工艺，其肝素或肝素结构在 α-L-iduronic-2-O-sulfate 酸的第 2 位发生了改变，其中的硫酸基全部或部分被亲核基取代。 所述工艺是通过在碱性介质中使用亲核剂处理具有肝素或肝素结构的糖胺聚糖来实现的。
• Process for the synthesis of semisynthetic glycosaminoglycans containig alpha-L-galacturonic acid substituted with nucleophilic radicals in position 3
  申请人：ALFA WASSERMANN S.p.A.

  公开号：EP0618235A1

  公开（公告）日：1994-10-05

  A process for the synthesis of semi-synthetic glycosaminoglycans of general formula III is described in which one of the saccharide units characteristic of glycosaminoglycans with heparin or heparan structure, more specifically that of α-L-iduronic-2-O-sulfate acid, has undergone a structural modification, entirely or in part, with transformation into α-L-galacturonic acid substituted in position 3 with nucleophilic radicals of general formula II Said process is carried out by treating glycosaminoglycans with heparin or heparan structure by means of a nucleophilic reagent in alkaline medium.

  通式 III 的半合成糖胺聚糖的合成工艺 描述了具有肝素或肝糖结构的糖胺聚糖所特有的一个糖单位，更具体地说是 α-L-iduronic-2-O-sulfate 酸的糖单位，在结构上全部或部分发生了改变，变成了在第 3 位被通式 II 的亲核基取代的 α-L-半乳糖醛酸。 上述过程是在碱性介质中通过亲核试剂处理具有肝素或肝素结构的糖胺聚糖。